| Du, Xin |
NCT03873311: Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy |
|
|
| Recruiting | 4 | 114 | RoW | Azacytidine, HAG Regimen, Azacytidine, HAG Regimen (HHT Cytarabine G-CSF), Azacytidine | Shenzhen Second People's Hospital | Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia | 12/22 | 06/23 | | |
NCT04155411: Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP |
|
|
| Recruiting | 4 | 65 | RoW | Dasatinib | Shenzhen Second People's Hospital | Dasatinib, BCR-ABL, Chronic Myeloid Leukemia | 12/22 | 12/23 | | |
NCT04933526: The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients |
|
|
| Recruiting | 4 | 118 | RoW | Flumatinib, Dasatinib | Shenzhen Second People's Hospital | Chronic Myeloid Leukemia in Chronic Phase | 04/23 | 06/23 | | |
NCT04677439: Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure |
|
|
| Recruiting | 4 | 200 | RoW | Flumatinib | Shenzhen Second People's Hospital, Hainan General Hospital, Sanya Central Hospital, First Affiliated Hospital of Shantou University Medical Collegeity, Peking University Shenzhen Hospital, Dongguan People's Hospital | Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib | 05/23 | 12/23 | | |
NCT03942094: Nilotinib for First-line Newly Diagnosed CML-CP Patients |
|
|
| Recruiting | 3 | 100 | RoW | Nilotinib | Shenzhen Second People's Hospital, Zhongshan City People's Hospital, The Affiliated Hospital of Guangdong Medical College, Huazhong University of Science and Technology Union Shenzhen Hospital, Dongguan People's Hospital, Longgang District Central Hospital of Shenzhen | Chronic Myeloid Leukemia, Chronic Phase, Nilotinib | 06/23 | 12/23 | | |
NCT05311943: Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. |
|
|
| Recruiting | 3 | 40 | RoW | olverembatinib, HQP1351 | Shenzhen Second People's Hospital | Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors | 06/24 | 06/25 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 12/25 | 12/25 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
| Recruiting | 2 | 105 | RoW | TQ05105 tablets, Hydroxycarbamide tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Moderate and High Risk Myelofibrosis | 03/23 | 09/23 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT06451861: Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML |
|
|
| Not yet recruiting | 2 | 240 | RoW | Chidamide, Venetoclax, azacitidine, Anthracyclines or anthraquinones, idarubicin, daunorubicin, mitoxantrone, cytarabine | Guangdong Provincial People's Hospital | Acute Myeloid Leukemia | 12/26 | 06/27 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) |
|
|
| Terminated | 1/2 | 15 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Myelodysplastic Syndrome | 09/23 | 09/23 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 160 | US, RoW | SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine | Sellas Life Sciences Group, Sellas Life Sciences Group | Hematologic Malignancies | 06/25 | 12/25 | | |
NCT05192486: A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 1/2 | 20 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Diffuse Large B-cell Lymphoma | 06/25 | 12/25 | | |
NCT02559830: Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy |
|
|
| Recruiting | 1/2 | 50 | RoW | transduced CD34+ hematopoietic stem cell | Shenzhen Second People's Hospital, Shenzhen University, Guangzhou Women and Children's Medical Center | Metachromatic Leukodystrophy, Adrenoleukodystrophy | 10/25 | 10/25 | | |
| Recruiting | N/A | 98 | RoW | | Shenzhen Second People's Hospital | Leukemia, Myelogenous, Chronic, BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia), Positive | 09/22 | 10/22 | | |
| Recruiting | N/A | 1000 | RoW | 99mTc-DTPA, technetium-99m-labeled diethylenetriaminepentaacetic acid | Nanjing First Hospital, Nanjing Medical University | Kidney; Disease (Functional), Chronic Kidney Disease | 12/24 | 12/25 | | |
NCT06427096: Effect of Healthy Family Program on Population Blood Pressure |
|
|
| Recruiting | N/A | 8000 | RoW | Multifaceted intervention | Heart Health Research Center | Blood Pressure | 02/25 | 08/25 | | |
| Recruiting | N/A | 1675 | RoW | Intensive BP Control, Control of home SBP to a target of 120mmHg, Standard BP Control, Control of home SBP to a target of 135mmHg | Beijing Anzhen Hospital, Heart Health Research Center, The George Institute for Global Health, China, The George Institute for Global Health, Australia, Fukuoka University | Atrial Fibrillation, Hypertension | 06/24 | 12/25 | | |
| Gao, Yan |
NCT04994210: Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab, Tyvyt®, Chidamide, Epidaza | Sun Yat-sen University | Safety and Efficacy | 08/23 | 08/25 | | |
| Recruiting | 2 | 140 | RoW | WS016 3g, WS016 6g, WS016 12g, Matching Placebo | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Hyperkalemia | 04/24 | 08/24 | | |
| Recruiting | N/A | 493 | RoW | early detection test | Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd. | Lymphoma | 06/23 | 08/25 | | |
NCT05505487: Construction and Effect Evaluation of Integrated Care Model for Pulmonary Infection in Stroke Patients With Tracheotomy |
|
|
| Recruiting | N/A | 80 | RoW | integrated care model | Shenzhen Second People's Hospital | Stroke, Pulmonary Infection | 05/26 | 05/26 | | |
| Zhou, Jie |
| Recruiting | 3 | 306 | RoW | Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant | Sichuan University | Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | 12/25 | 12/25 | | |
NCT03598465: Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure |
|
|
| Completed | N/A | 591 | RoW | | Nanfang Hospital, Southern Medical University | Post-hepatectomy Liver Failure | 09/24 | 10/24 | | |
NCT06401993: Peripheral-central Correlation Study on the Treatment of Chronic Tinnitus With "Dao qi Tong Luo" Based on the Theory of "Connecting the Two Ears to the Brain" |
|
|
| Recruiting | N/A | 87 | RoW | The "dao qi tong luo" group, The acupuncture group | The Third Affiliated hospital of Zhejiang Chinese Medical University | Tinnitus | 08/26 | 12/26 | | |
NCT04119986: Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study ) |
|
|
| Not yet recruiting | N/A | 220 | RoW | drug coated balloon, drug eluted stent | Nanjing First Hospital, Nanjing Medical University | Coronary Heart Disease | 12/26 | 12/26 | | |
| Not yet recruiting | N/A | 82 | NA | electroacupuncture, Acupuncture | The Third Affiliated hospital of Zhejiang Chinese Medical University | Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | 12/24 | 12/24 | | |
NCT04793373: Superiority of Epidural Placement Technique Using EpiFaith Syringe |
|
|
| Withdrawn | N/A | 680 | US | Syringe | Harvard Medical School (HMS and HSDM) | Anesthesia | 12/25 | 06/26 | | |
NCT04662450: Evaluation and Management of Parturients' Pain Intensity |
|
|
| Withdrawn | N/A | 90 | NA | ABM affective pain stimuli, ABM sensory pain stimuli, Placebo | Harvard Medical School (HMS and HSDM) | Labor Pain | 09/26 | 12/26 | | |
| Withdrawn | N/A | 100 | NA | Cognitive Bias Modification for Interpretation (CBM-I), Placebo | Harvard Medical School (HMS and HSDM) | Anxiety | 09/26 | 12/26 | | |
NCT05410665: The Roles of IL-9/E-cadherin and Ferroptosis in Intestinal Mucosal Barrier Injury in Sepsis |
|
|
| Recruiting | N/A | 100 | RoW | Standard treatments for sepsis | Nanjing First Hospital, Nanjing Medical University | Sepsis, Intestinal Mucosal Barrier, Ferroptosis | 12/23 | 06/24 | | |
| Park, Hye Soon |
NCT04536675: Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery |
|
|
| Recruiting | 3 | 204 | RoW | Vilanterol and Umeclidinium Bromide, Placebo | Samsung Medical Center | Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer | 11/23 | 04/24 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Novartis Pharmaceuticals | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
NCT05906264: Pulmonary Rehabilitation Program in COPD Patient |
|
|
| Recruiting | N/A | 64 | RoW | Tele-intervention | Samsung Medical Center | Chronic Obstructive Pulmonary Disease | 08/23 | 09/23 | | |
NCT05148052: Effect of Upper Extremity Rehabilitation Using Immersive Virtual Reality in Chronic Stroke Patients. |
|
|
| Recruiting | N/A | 36 | RoW | Virtual reality exergames, Conventional occupational therapy | Seoul National University Hospital, Asan Medical Center, National Traffic Injury Rehabilitation Hospital, Korea Workers' Compensation and Welfare Service Incheon Hospital | Stroke | 08/25 | 10/25 | | |
NCT05820815: Feasibility and Safety of In-bed Self-exercise in Patients With Subacute Stroke |
|
|
| Recruiting | N/A | 24 | RoW | in-bed self-exercises based on EMG-sensor feedback intervention | Seoul National University Hospital, Ministry of Trade, Industry & Energy, Republic of Korea | Stroke | 06/26 | 12/26 | | |
| ren, lijie |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 04/25 | | |
| Wang, Xianming |
NCT02062489: Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients |
|
|
| Recruiting | 3 | 688 | RoW | Tamoxifen, Nolvadex, Placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 05/25 | 05/26 | | |
| Yan, Dewen |
NCT04553380: Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin |
|
|
| Not yet recruiting | N/A | 150 | NA | basic insulin, Glargine 300U/3ml | Shenzhen Second People's Hospital | Type 2 Diabetes | 12/21 | 03/22 | | |
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes |
|
|
| Recruiting | N/A | 20000 | RoW | Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center | Second Xiangya Hospital of Central South University | Type1diabetes, Diabetes | 12/35 | 12/35 | | |
| PhD |
NCT03642028: Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress |
|
|
| Recruiting | 4 | 144 | US | Suvorexant, Belsomra, Placebo | VA Office of Research and Development | Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic | 12/25 | 12/25 | | |
NCT05235919: Treatment to Promote Self-regulation in Children With Autism Spectrum Disorder |
|
|
| Recruiting | 2 | 50 | Canada | repetitive transcranial magnetic stimulation (rTMS), Sham stimulation | Holland Bloorview Kids Rehabilitation Hospital, Centre for Addiction and Mental Health, University of Toronto | Autism Spectrum Disorder, Self-Regulation, Emotion | 02/25 | 02/25 | | |
HB0025-C-01, NCT06758557: A Phase Ib/II Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 282 | RoW | HB0025, Pemetrexed, Paclitaxel, Carboplatin | Huabo Biopharm Co., Ltd. | Advanced NSCLC, Advanced Endometrial Cancer | 10/25 | 02/26 | | |
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) |
|
|
| Recruiting | 1 | 24 | RoW | RC48-ADC, RC48-ADC injection, RC98, RC98 injection | RemeGen Co., Ltd. | Gastric Cancer | 05/24 | 09/24 | | |
NCT04729673: Canine Occlusal Relationship Changes After Full Mouth Rehabilitation Under General Anesthesia |
|
|
| Completed | N/A | 73 | RoW | Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd) | Cairo University | General Anesthesia | 08/22 | 03/23 | | |
NCT05633706: Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis |
|
|
| Recruiting | N/A | 150 | Canada | fluid biopsy capsule | Nimble Science Ltd. | Irritable Bowel Syndrome, Crohn Disease, Celiac Disease, Ulcerative Colitis, Functional Dyspepsia | 12/24 | 01/25 | | |
| Recruiting | N/A | 70 | Europe | | Universiteit Antwerpen, University Hospital, Antwerp | Tuberous Sclerosis, STXBP1 Encephalopathy With Epilepsy | 12/24 | 02/25 | | |
NCT06183021: The Effect of Cryotherapy on the Outcome of Pulpotomy and Root Canal Treatment |
|
|
| Recruiting | N/A | 144 | RoW | Vital pulp cryotherapy, Intracanal cryotherapy | Ondokuz Mayıs University | Pulpitis, Caries; Dentin, Pain, Postoperative | 01/25 | 12/25 | | |
POWER, NCT05327465: Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy |
|
|
| Recruiting | N/A | 62 | US | Aerobic and resistance exercise, Usual Care | Dana-Farber Cancer Institute, Pfizer, Prostate Cancer Foundation | Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic | 12/25 | 06/26 | | |
NCT04489992: Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System |
|
|
| Recruiting | N/A | 133000 | RoW | | Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department | AI (Artificial Intelligence), Mammary Cancer, Lung Cancer, X-Rays; Lesion, COVID-19, Chest--Diseases, Abdomen Disease, Brain Disease, Fractures, Bone | 01/24 | 01/24 | | |
| Recruiting | N/A | 30 | RoW | Exercise, Combined Exercise + Diet | Charles University, Czech Republic, Ministry of Health, Czech Republic, EXCELES LX22NPO5104, CarDia | Obesity | 12/25 | 04/26 | | |
RESTART, NCT05236062: Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the Trial |
|
|
| Recruiting | N/A | 36 | US | Exercise, Attention control | Dana-Farber Cancer Institute | Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease | 01/25 | 10/25 | | |
RE-BUILD, NCT05356117: Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The Trial |
|
|
| Recruiting | N/A | 45 | US | Resistance Training (RT) and Protein Supplementation (PS), Resistance Training (RT), Attention Control (AC | Dana-Farber Cancer Institute | Pancreatic Cancer | 01/25 | 08/25 | | |
HYPE, NCT05740839: High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study |
|
|
| Recruiting | N/A | 30 | US | HIIT Exercise Program, High-Intensity Interval Training, Control Group | Dana-Farber Cancer Institute, Stahl Family Charitable Foundation, The Childhood Brain Tumor Foundation, Pedals For Pediatrics | Pediatric Brain Tumor | 01/25 | 05/25 | | |
| Not yet recruiting | N/A | 27 | RoW | Universal Design Model, Design, Implementation and Evaluation of School Health Nursing Course Curriculum Based on Universal Design Model | Duzce University | Nursing Education | 06/24 | 12/25 | | |
| Recruiting | N/A | 9 | RoW | Subperiosteal implant framework | Menoufia University | Bone Loss | 06/24 | 07/24 | | |
NCT02451683: Corticospinal Function After Spinal Cord Injury |
|
|
| Recruiting | N/A | 300 | US | Electrophysiology Assessment of Time Domain, Electrophysiology Assessment of Location, Training with some stimulation | Shirley Ryan AbilityLab, National Institute of Neurological Disorders and Stroke (NINDS) | Spinal Cord Injury | 12/25 | 12/26 | | |
BALANCAR, NCT06345625: Gait and Postural Balance Analysis During Head-motion Perturbed Standing and Walking in Older Adults |
|
|
| Recruiting | N/A | 100 | Europe | Cognition, Sensory function, Frailty, Biomechanical movement analysis, Screening, Follow up | Universiteit Antwerpen | Aged, Accidental Fall, Postural Balance, Gait | 01/27 | 01/28 | | |
NCT06302296: Evaluating the Effect of Injectable Platelet-rich Fibrin on Accelerating Orthodontic Tooth Movement |
|
|
| Recruiting | N/A | 14 | RoW | injectable form of PRF, Placebo injection | Hama University | Tooth Mobility, Injectable Platelet-rich Fibrin | 05/25 | 07/25 | | |
NCT02344121: Intra- and Inter-fraction Changes in Radiation Therapy |
|
|
| Recruiting | N/A | 500 | US | Radiation Therapy | Medical College of Wisconsin | Cancer | 12/24 | 01/30 | | |
THRIVE, NCT05327452: Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the Study |
|
|
| Recruiting | N/A | 135 | US | Supervised Home-Based Exercise, Unsupervised Home-Based Exercise, Attention Control | Dana-Farber Cancer Institute, National Cancer Institute (NCI), University of Massachusetts, Boston | Breast Cancer, Colorectal Cancer, Prostate Cancer | 08/25 | 12/25 | | |
NCT05505487: Construction and Effect Evaluation of Integrated Care Model for Pulmonary Infection in Stroke Patients With Tracheotomy |
|
|
| Recruiting | N/A | 80 | RoW | integrated care model | Shenzhen Second People's Hospital | Stroke, Pulmonary Infection | 05/26 | 05/26 | | |
NCT05838586: Sex Differences in the effecTs of brEaking uP Sedentary Behavior on vascUlar Function in Type 2 Diabetes |
|
|
| Recruiting | N/A | 80 | US | prolonged SB, SB broken 1, SB broken 2 | University of Minnesota | Type 2 Diabetes, Cardiovascular Diseases | 07/26 | 07/26 | | |
| Recruiting | N/A | 144 | US | Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active), Transcranial electrical stimulation (tES), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham), Transcranial electrical stimulation (sham condition), Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham), tACS active; tDCS sham, Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active), tACS sham; tDCS active | Hebrew SeniorLife, BrightFocus Foundation, National Institute on Aging (NIA) | Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation | 12/26 | 08/27 | | |
NCT04996095: The Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan |
|
|
| Recruiting | N/A | 400 | RoW | | National Health Research Institutes, Taiwan, National Cheng-Kung University Hospital, National Taiwan University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital | Esophageal Cancer | 12/29 | 12/29 | | |
| Ye, Min |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
| Lu, Yongtian |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
NCT06235203: Neoadjuvant Vs Adjuvant in Locally Advanced Recurrent NPC |
|
|
| Recruiting | 3 | 154 | RoW | endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy | Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi, Shenzhen Second People's Hospital | Recurrent Nasopharyngeal Carcinoma | 06/27 | 06/27 | | |
NCT06228079: Adjuvant Vs Surgery Only in Early-stage Recurrent NPC |
|
|
| Recruiting | 3 | 176 | RoW | Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen | Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi, Shenzhen Second People's Hospital | Recurrent Nasopharyngeal Carcinoma | 06/28 | 06/28 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT05011227: Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 100 | RoW | Camrelizumab, Chemotherapy, endoscopic surgery | Eye & ENT Hospital of Fudan University, Chinese Academy of Medical Sciences | Recurrent Nasopharyngeal Carcinoma | 08/25 | 08/25 | | |
NCT05350891: Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC |
|
|
| Recruiting | 2 | 77 | RoW | endoscopic surgery, adjuvant immunotherapy, chemotherapy | Eye & ENT Hospital of Fudan University, Chinese Academy of Medical Sciences | Recurrent Nasopharyngeal Carcinoma | 05/26 | 05/26 | | |
| Tang, Juan |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
| Guowen, Liu |
NCT05602792: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 233 | RoW | T3011 | ImmVira Pharma Co. Ltd | Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer | 07/23 | 01/24 | | |
| Wang, Meiying |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
| Recruiting | N/A | 2000 | RoW | | Peking Union Medical College Hospital | Anti Phospholipid Syndrome | 12/26 | 12/26 | | |
| Shen, Jianzhen |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
| Liu, Chaokai |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
| Jiang, Danxian |
NCT06455410: GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 216 | RoW | GP, Adebrelimab, concurrent chemoradiotherapy (CCRT) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/26 | 06/28 | | |
| Miao, Beiping |
NCT06455410: GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 216 | RoW | GP, Adebrelimab, concurrent chemoradiotherapy (CCRT) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/26 | 06/28 | | |
